Product Description
HIZIUM LS Capsules combine Esomeprazole and Levosulpiride to provide complementary actions in gastrointestinal care. Esomeprazole reduces gastric acid secretion by inhibiting the proton pumps in the stomach, while Levosulpiride acts on dopamine receptors and supports gastrointestinal motility. The enteric-coated and sustained-release pellet systems are designed to provide their respective release characteristics.
Target Speciality
- Gastroenterology
Key Attributes
- Acid-Secretion Control: Esomeprazole helps reduce gastric acid production through proton pump inhibition.
- Gastrointestinal Motility Support: Levosulpiride supports coordinated movement of the gastrointestinal tract.
- Dual-Action Combination: Combines acid suppression with a prokinetic component.
- Enteric-Coated Pellets: Esomeprazole is presented in an enteric-coated form to protect it from gastric acid.
- Sustained-Release Pellets: Levosulpiride is formulated for gradual release.
Disclaimer
This information is for general reference only and does not replace professional medical advice. To be administered only under medical supervision. Not for public promotion.
Frequently Asked Questions
- Is monopoly available for HIZIUM LS Capsules?
Yes. District-wise monopoly rights are offered across India. Tell us your district and we will confirm availability.
- What is the composition of HIZIUM LS Capsules?
Each capsule contains Esomeprazole 40 mg as enteric-coated pellets and Levosulpiride 75 mg as sustained-release pellets.
- Are HIZIUM LS Capsules manufactured at a WHO-GMP-certified facility?
Yes. Manufacturing follows GLP, WHO, ISO and GMP norms, and every batch is assayed for actual content before dispatch.
- What is the minimum order quantity (MOQ) for HIZIUM LS Capsules?
The minimum order quantity may vary depending on the product and business requirements. Please contact our team for current MOQ and pricing details.










